I think another six months.The BIT225-010 Phase 2 HIV-1 trial...

I think another six months.

The BIT225-010 Phase 2 HIV-1 trial that was run at sites in Thailand included people newly diagnosed as being
HIV-1 positive but not yet commenced ART with BIT225 treatment or placebo continuing for six months in
combination with ART. This extended dosing period allows for a more detailed investigation of immune changes
observed in previously completed HIV-1 clinical studies with BIT225. The endpoints for this trial include
measurements of improved immune function and markers linked to immune reconstitution.